These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12452368)

  • 1. Effect of ursodeoxycholic acid on hepatic steatosis in rats.
    Okan A; Astarcioglu H; Tankurt E; Sagol O; Altekin E; Astarcioglu I; Gonen O
    Dig Dis Sci; 2002 Nov; 47(11):2389-97. PubMed ID: 12452368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
    Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
    World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid treatment of hepatic steatosis: a (13)C NMR metabolic study.
    Nunes PM; Jones JG; Rolo AP; Palmeira CM; Carvalho RA
    NMR Biomed; 2011 Nov; 24(9):1145-58. PubMed ID: 21538633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
    Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [UDCA in the treatment of nonalcoholic fatty liver disease].
    Grigor'eva IN
    Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver.
    Lukivskaya OY; Maskevich AA; Buko VU
    Alcohol; 2001 Oct; 25(2):99-105. PubMed ID: 11747979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
    Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
    BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity.
    Uraz S; Tahan V; Aygun C; Eren F; Unluguzel G; Yuksel M; Senturk O; Avsar E; Haklar G; Celikel C; Hulagu S; Tozun N
    Dig Dis Sci; 2008 Apr; 53(4):1071-7. PubMed ID: 17934844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of NASH with ursodeoxycholic acid: pro.
    Ratziu V
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of NASH with ursodeoxycholic acid: cons.
    Liechti F; Dufour JF
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
    Lukivskaya O; Zavodnik L; Knas M; Buko V
    Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid.
    Azer SA; Canfield PJ; Stacey NH
    J Gastroenterol Hepatol; 1995; 10(3):261-9. PubMed ID: 7548801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].
    Belonovskaia EB; Naruta EE; Lukivskaia OIa; Abakumov VZ; Buko VU
    Eksp Klin Farmakol; 2013; 76(1):25-9. PubMed ID: 23461012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.